The company provide in vitro and in vivo facilities to pharmaceutical companies to conduct clinical trials, including internal IRB and external regulatory approvals.  Currently, seek approval of clinical trial of NLRP3, Caspase1 inhibitors and anti-interleukin (IL)-18 for eosinophilic asthma, eosinophils associated gastrointestinal disorders and chronic inflammation-induced chronic pancreatitis associated pancreatic malignancy and metastasis. Further, the company is the first to implicate NLRP3 regulated IL-18 and eosinophils to the progression of pancreatic cancer and metastasis.  Additionally, our focused research is to establish noninvasive biomarkers for chronic pancreatitis, and the mediators responsible for promoting fibroblast heterogeneity, plasticity and cancer associated fibroblast (CAFs) development.